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TRAP  and  PON1,  197  healthy,  91  with  unipolar  depression  and  45  with  bipolar  disorder.
PON1,  male  gender,  RR genotype  and  body  mass  index  are  inversely  correlated  with  TRAP.
PON1  activity,  interactions  between  PON1  Q192R  genotypes  and  smoking  inﬂuence  TRAP.
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a  b  s  t  r  a  c  t
The  measurement  of  the  total  radical  trapping  antioxidant  potential  (TRAP)  is a general  marker  of  periph-
eral  blood  antioxidant  defenses.  Paraoxonase  1 (PON1)  is  a potent  antioxidant,  which  protects  against
lipid  peroxidation.  The  study  aimed  to  examine  the relation  between  TRAP  levels  and  PON1  activity,
PON1  Q192R  functional  genotypes,  smoking,  interactions  between  PON1  genotypes  and  smoking,  and
mood  disorders,  while  adjusting  for effects  of  ethnicity,  marital  status,  body  mass  index  (BMI)  and  gender.
The  analyses  were  performed  in 197  controls  and  136  subjects  with  mood  disorders.  TRAP levels  were
signiﬁcantly  associated  with  higher  plasma  PON1  activity,  the  RR  functional  genotype,  non  smoking  by
RR  carriers,  male  gender  and a higher  BMI.  TRAP  levels  were  signiﬁcantly  lower  in patients  with  mood
disorders  than  in controls,  but  this  association  was  no longer  signiﬁcant  after  considering  the  effectsepression
ody mass index
of  the above  predictors.  The  risk  in  the  subgroup  with  low  TRAP  levels  is increased  by a smoking  X  RR
genotype  interaction  and  decreased  by  male  gender,  the  RR  genotype,  and  higher BMI  and  PON1  activ-sychiatry ity.  Plasma  PON1  activity,  the  PON1  Q192R  functional  genotypes  and  speciﬁc  interactions  between  this
genotype  and  smoking  contrib
TRAP  levels.
Abbreviations: ANCOVAs, analysis of covariance; ANOVAs, analysis of variance; ASS
MI,  body mass index; CMPA, 4-chloromethyl phenol acetate; DSM-IV, diagnostic and sta
ipoprotein; HDRS, Hamilton depression rating scale; LDL, low-density lipoprotein; OS, 
pecies;  SEM, standard error of the mean; TRAP, total radical trapping antioxidant potent
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IST, alcohol, smoking and substance involvement screening; BD, bipolar disorder;
tistical manual of mental disorder; GLM, general linear analysis; HDL, high-density
oxidative stress; PA, phenyl acetate; PON1, paraoxonase 1; ROS, reactive oxygen
ial; TUD, tobacco use disorder.
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. Introduction
Cigarette smoke contains hundreds of compounds which act as
ro-oxidants and produce reactive oxygen species (ROS). Smoking
nhances oxidative stress (OS) and decreases antioxidant defense
echanisms [1]. Mood disorders, including major depression and
ipolar disorder (BD), are accompanied by increased OS and low-
red levels of antioxidants [2].
One major measure of total plasma antioxidant defense is the
otal radical trapping antioxidant potential (TRAP) in plasma [3].
n important antioxidant enzyme is paraoxonase 1 (PON1), which
s lowered in individuals with mood disorders and tobacco use dis-
rder (TUD) [4]. PON1 is an enzyme synthesized in the liver, and
ecreted into plasma where it is bound to high-density lipoprotein
HDL) particles. These protect against lipoprotein peroxidation, a
ey process underpinning the pathophysiology of atherosclerosis
5]. Polymorphisms of the PON1 gene determine PON1 enzymatic
ctivities, e.g. the polymorphism with Q/R substitution at position
92 [4,5]. This functional Q192R polymorphism determines PON1
nzyme activity which in turn protects low-density lipoprotein
LDL) from oxidation. In this regard the Q192 alloenzyme is more
fﬁcient than the R192 aloenzyme [5].
The aim of this study is to examine whether TRAP levels are
ssociated with PON1 status, smoking, mood disorders, interac-
ions between the PON1 Q192R genotypes and smoking, ethnicity,
arital status, body mass index (BMI) and gender.
. Subjects and methods
.1. Subjects
The participants were 197 normal controls, 91 patients with
ajor depression and 45 with BD recruited at the State Uni-
ersity of Londrina. Participants of Caucasian, Asian, African and
ixed ethnicities, aged 18–65 years, were enrolled in this study.
he diagnoses of BD, depression and tobacco use disorder (TUD,
urrent smokers) were made using a validated Portuguese ver-
ion of the Diagnostic and Statistical Manual of Mental Disorders
DSM-IV) [6]. All TUD subjects were current smokers who  at the
ime of interview reported smoking every day or some days.
ood disorder patients in the acute phase of illness and in par-
ial or total remission were included. Subjects with diagnoses other
han depression and BD (e.g. schizophrenia, substance abuse dis-
rders, and psycho-organic syndromes) were excluded. Normal
ontrols were individuals without a lifetime or current diagnosis of
xis I.
We  excluded individuals with abnormal values of hemogram,
spartate transaminase, alanine transaminase, urea, creatinine;
ho suffered from diabetes, (auto)immune disorders, chronic
bstructive pulmonary disorder, inﬂammatory bowel disease,
nd neuroinﬂammatory disorders; who were treated with
mmunomodulatory drugs or antioxidant supplements.
The severity of depression was measured using a validated Por-
uguese version of the Hamilton Depression Rating Scale (HDRS)
7]. The Alcohol, Smoking and Substance Involvement Screening
est (ASSIST) was used to assess risk levels of alcohol use [8].
MI  was calculated as weight (kg)/body height (in meter)2. The
tudy was approved by the Research Ethics Committee (number
50/2010). All participants gave written informed consent prior to
articipating in this study..2. Laboratory assessments
Blood was sampled after an overnight fast. TRAP was measured
y chemiluminescence in an adaptation of the method describede Letters 581 (2014) 46–51 47
by Repetto et al. (1996) [9]. A comparison of the induction time
after the addition of known concentrations of Trolox and plasma is
used to measure TRAP values of Trolox equivalents.
PON1 status was determined as described by Richter et al. (1999)
[10]. 4-Chloromethyl phenol acetate (CMPA) hydrolysis and phenyl
acetate (PA) hydrolysis under high salt conditions was measured in
a microplate spectrophotometer. The results obtained with these
two assays were used to plot a 2-dimensional enzyme activity
graphic that displays rates of arylesterase activity under high salt
conditions versus CMPase activity. Since the polymorphism Q192R
confers differential catalytic activity against these two  substrates,
the plot splits the population into the three functional positions 192
genotype (QQ, QR and RR). Measurement of PA hydrolysis at low
salt concentrations reveals plasma PON1 activity since at this condi-
tion PON1 Q192R polymorphism does not inﬂuence PON1 catalytic
activity against PA [10].
2.3. Statistics
Analyses of variance (ANOVAs) and covariance (ANCOVAs) were
performed to examine differences between treatments means fol-
lowed by Tukey’s test. Analyses of contingency tables (2 tests)
were performed to ascertain differences in the distribution of
variables between diagnostic categories. Relationships between
variables were checked using Pearson’s correlation coefﬁcients and
stepwise General linear model (GLM) analyses. We  used automatic
stepwise binary logistic regression analyses to examine the associa-
tions between patients with lower TRAP levels (versus higher TRAP
levels, median-split dichotomized) as dependent variable and dif-
ferent explanatory variables, including PON1 status, smoking, BMI,
gender, etc. The data were analyzed using SPSS and the statistical
signiﬁcance set at  ˛ = 0.05 (two tailed).
3. Results
3.1. Plasma TRAP measurements
Table 1 shows that TRAP levels were signiﬁcantly lower in
women than in men. There were no signiﬁcant associations
between TRAP levels and ethnicity or marital status. Patients had
signiﬁcantly lower plasma TRAP levels than controls. TUD patients
had signiﬁcantly lower TRAP levels than non-smokers. There were
no signiﬁcant differences in TRAP values between QQ, QR and RR
carriers.
In the total study group, there were no signiﬁcant correla-
tions between plasma TRAP levels and age (r = −0.003, p = 0.952,
n = 333), years of education (r = 0.059, p = 0.286, n = 333), and alcohol
use (r = 0.082, p = 0.137, n = 332). There were signiﬁcant correla-
tions between plasma TRAP and PON1 activity (r = 0.125, p = 0.022,
n = 333), BMI  (r = 0.202, p < 0.001, n = 333) and HDRS (r = −0.200,
p < 0.001, n = 332).
Table 2 shows the results of GLM analyses with TRAP as depend-
ent variable and age, BMI, years of education, plasma PON1 activity,
HDRS, use of alcohol, gender, smoking, PON1 Q192R genotypes
(entered as QQ + QR versus RR), diagnosis (entered as controls
versus patients or as controls versus depression versus BP disor-
der), marital status, and ethnicity as explanatory variables. 28.4%
of the variance in plasma TRAP levels was explained by PON1, the
interaction smoking by PON1 Q192R genotypes, BMI  and gender
(F = 16.03, df = 8/324, p < 0.001). PON1, BMI, male gender and the
RR genotype were signiﬁcantly associated with increased TRAP
levels. TRAP was signiﬁcantly higher in RR than in QQ (p = 0.009)
and QR (p = 0.024) carriers, but there were no signiﬁcant differ-
ences between QQ and QR carriers (p = 0.642). The interaction
pattern showed that non smoking in subjects with a RR and
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Table 1
Measurements of total radical trapping antioxidant potential (M Trolox) in 333 subjects.
Variables Type n Mean (SD) F df p
Gender Men
Women
115
218
901.4 (132.6)
785.3 (138.2)
60.43 1/331 <0.001
Ethnicity Caucasian
African Asian
Mixed
228
50
55
825.6 (138.6)
838.2 (126.6)
812.8 (134.0)
0.46 2/330 0.634
Marital status Single
Stable
Separated,
widowed
49
221
63
834.6 (119.5)
825.0 (141.2)
819.7 (130.6)
0.17 2/330 0.845
Diagnosis Controls
Mood disorders
197
136
839.6(136.5)
804.9 (132.9)
5.43 1/331 0.020
Diagnosis Controls
Depression
Bipolar disorder
197
91
45
839.6 (136.5)
808.2 (136.8)
798.1 (125.8)
2.75 2/330 0.065
TUD  No
Yes
190
143
837.7 (133.2)
809.1 (138.2)
4.05 1/331 0.045
PON1  Q192R
Genotypes
QQ QR RR 151
132
50
822.0 (127.7)
817.9 (140.9)
855.4 (144.9)
1.36 2/330 0.258
Mood disorders: depression and bipolar disorder.
TUD: tobacco use disorder.
Table 2
Results of general linear model analysis with total radical trapping antioxidant potential as dependent variable and the listed variables as explanatory variables.
Variables F df p 
Plasma PON1 5.87 1/324 0.016 0.018
Smoking X PON1 Q192R genotypes 3.76 5/324 0.003 0.055
Body  mass index 26.59 1/324 <0.001 0.076
Gender (male) 88.45 1/324 <0.001 0.214
PON1: paraoxonase 1.
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tion, subjects with mood disorders displayed lowered TRAP levels
than controls, although these effects were not signiﬁcant in theON1 Q192R genotypes: entered as QR and RR genotypes with QQ as reference gro
:  partial 2.
R genotype is associated with increased TRAP levels: TRAP lev-
ls were signiﬁcantly higher in non-smokers than in smokers in
R (adjusted mean ± SEM = 875.0 ± 14.3 versus 806.7 ± 15.4 M
rolox) and RR (906.3 ± 25.5 versus 863.6 ± 21.9 M Trolox)
arriers (the means were obtained by GLM analysis after adjus-
ing for the abovementioned background variables). There were
o differences in TRAP between QQ smokers (833.0 ± 16.0 M
rolox) and QQ non smokers (835.2 ± 12.3 M Trolox). All other
ariables were not signiﬁcant in this regression analysis includ-
ng diagnostic classiﬁcations. In addition, forced entry of the
hree diagnostic groups (depression, bipolar disorder and con-
rols) showed that these diagnostic groups were not signiﬁcant
n predicting TRAP (F = 1.20, df = 2/322, p = 0.301), while PON1
F = 6.11, df = 1/322, p = 0.014), smoking X PON1 Q192R geno-
ypes (F = 3.60, df = 5/322, p = 0.004), BMI  (F = 28.15, df = 1/322,
 < 0.001) and gender (F = 84.30, df = 1/322, p < 0.001) remained
igniﬁcant in predicting TRAP. ANOVA showed that in TUD sub-
ects, TRAP was not signiﬁcantly different (F = 1.56, df = 2/140,
 = 0.213) between QQ (mean ± SD = 822.9 ± 109.9 M Trolox,
 = 54), QR (785.4 ± 146.8 M Trolox, n = 60) and RR individuals
832.2 ± 162.6 M Trolox, n = 29).
We  examined the effects of psychotropic drugs on our
esults. There were no signiﬁcant differences (F = 0.08, df = 1/331,
 = 0.775) in TRAP levels between subjects without (mean ± SD
24.6 ± 135.7 M Trolox, n = 296) and with psychotropic drug use
831.4 ± 139.7 M Trolox, n = 37). We  re-ran the above GLM anal-
sis in subjects who were drug free. 30% of the variance in TRAP
as explained (F = 15.38, df = 8/287, p < 0.001) by PON1 (F = 4.63,
f = 1/287, p = 0.016), smoking X PON1 Q192R genotypes (F = 3.05,
f = 5/287, p = 0.011), BMI  (F = 29.78, df = 1/287, p < 0.001) and gen-
er (F = 81.61, df = 1/287, p < 0.001).3.2. Characteristics of subjects with low versus high plasma TRAP
levels
We  dichotomized the study group into two  equal groups using
818.80 M Trolox as threshold value. Table 3 lists the characteris-
tics of subjects with lowered versus higher TRAP levels. There were
no signiﬁcant differences in age, ethnicity, marital status, diagnosis,
smoking, PON1 Q192R genotypic distribution, plasma PON1 activ-
ity and years of education between the two  study groups. Subjects
with lower TRAP levels showed a higher frequency of females and
a lower BMI  than subjects with higher TRAP levels.
Table 4 shows the results of an automatic stepwise logistic
regression analysis with the low TRAP subgroup as dependent vari-
able (<818.80 M Trolox) and all variables listed in Table 3 and the
interaction pattern smoking X PON1 Q192R genotypes as explana-
tory variables. We  found that using ﬁve predictors, 67.3% of all cases
were correctly classiﬁed (sensitivity = 70.7% and speciﬁcity = 63.9%;
2 = 72.61, df = 5, p < 0.001; Nagelkerke = 0.261). PON1, male gender,
BMI  and the RR genotype were inversely associated with the lower
TRAP subgroup, whereas the interaction smoking by RR carriers
increased the risk to belong to the low TRAP group.
4. Discussion
The ﬁndings of this study are that TRAP was signiﬁcantly related
to plasma PON1 activity, PON1 Q192R genotypes, an interaction
between smoking and these genotypes, BMI  and gender. In addi-ﬁnal regression analysis. TUD subjects showed lower levels of TRAP
than controls, but these effects were no longer signiﬁcant after
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Table  3
Characteristics of subjects divided into those with lower versus higher (median-dichotomized) total radical trapping antioxidant potential (TRAP) levels.
Variables Type Lower TRAP (n = 167) Higher TRAP (n = 166) F or X2 df p
TRAP (M)Trolox) – 718.3 (±76.6) 933.1(±89.4) 544.95 1/331 <0.001
Gender Men  Women 31136 8482 37.80 1 <0.001
Age  (years) – 46.3 (±8.2) 46.4 (±8.6) 0.00 1/331 0.946
Ethnicity Caucasian African
Asian Mixed
1132331 1152724 1.22 2 0.542
Marital status Single
Stable
Separated + widowed
2410736 2511427 1.52 2 0.467
Diagnosis Controls
Mood disorders
9176 10660 30.2 1 0.082
Diagnosis Controls
Depression
BD
914828 1064317 4.41 2 0.129
TUD  No
Yes
9077 10066 1.37 1 0.242
PON1  Q192R
Genotypes
QQ
QR
RR
787019 736231 3.53 2 0.171
Plasma PON1
(U/mL)
188.6 (±56.8) 196.1(±52.2) 1.55 1/331 0.213
BMI  (kg/m2) – 26.03 (±4.84) 27.86(±4.74) 12.20 1/331 0.001
Education (years) – 13.3 (±5.5) 13.6 (±6.8) 0.12 1/331 0.723
Results are shown as mean (±SD).
Results of analyses of variance (F) or analyses of contingence tables (X2 tests).
B
T
B
c
Q
h
w
[
a
l
R
t
a
o
t
R
a
t
R
r
i
r
i
e
O
e
a
T
R
v
C
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onsidering the interaction between current smoking and PON1
192R genotypes. TRAP levels were signiﬁcantly associated with
igher plasma PON1 activity. PON1 is a HDL-associated enzyme
ith multifunctional activities including antioxidant properties
11]. Therefore, our ﬁndings conﬁrm that this enzyme plays a role
s one of the antioxidants contributing to total TRAP levels.
The RR functional genotype was associated with higher TRAP
evels. These ﬁndings corroborate those of previous papers that the
R genotype is more protective against OS and that the QQ geno-
ype increases susceptibility to genotoxicity [12]. The Q isoform is
ssociated with a lowered protective activity against LDL and HDL
xidation and reduced paraoxon hydrolyzing activity [13]. Given
he role of OS in aging, it is also interesting to note that QR and
R carriers have a better survival advantage than Q allele carriers
nd those patients with a QQ genotype have worse diabetes control
han those with a RR genotype [14]. All in all, our data suggest that
R individuals are more protected than QQ carriers against OS.
We found that smoking decreased TRAP levels in RR and QR car-
iers. Thus, smoking has a stronger effect on antioxidant defenses
n RR and QR individuals than in QQ individuals. Chronic smoking is
elated to depletion of antioxidant levels [15], total plasma antiox-
dant capacity and PON1 plasma activity [16]. Moreover, the acute
ffects of smoking also result in increased lipid peroxidation [17].
ur study however shows that the genotype-smoking interaction
xplained more of the variance in plasma TRAP levels than smoking
lone, suggesting that the effects of smoking on total plasma TRAP
able 4
esults of automatic stepwise logistic regression analysis with lower versus higher (media
ariable and the listed variables as predictors.
Variables Wald df 
Plasma PON1 4.61 1 
PON1  Q192R genotypes 9.55 1 
Smoking (1) X PON1Q192R genotype 5.62 1 
Body  mass index 18.39 1 
Gender (male) 41.78 1 
I: 95% conﬁdence intervals.
ON1 Q192R genotypes: paraoxonase1 Q192R genotypes, QQ + QR versus RR.levels are attributable to the effects in QR and RR carriers only.
Future research should delineate whether the effects of smoking
enhancing oxidative biomarkers and decreasing speciﬁc antioxi-
dants are mediated by interactions between smoking and PON1
Q192R genotypes.
Our results showed that TRAP levels were signiﬁcantly higher in
males than in females. These results extend ﬁndings that women
may show higher levels of OS than men  [18]. For example, in a study
sample of normal volunteers and patients with chronic fatigue, we
found signiﬁcantly higher plasma peroxide levels in women than
in men  [18]. Such differences may  be associated with the lower
plasma TRAP levels in women  observed in our study. In preclin-
ical experiments of peripheral tissue antioxidant defenses were
higher in female than in male rats, while brain lipid peroxidation
was higher in males than in females [19]. Higher levels of vitamin
E and elevated activity of glutathione peroxidase were detected
in females [20–22]. Estrogens have signiﬁcant antioxidant proper-
ties, although the exact mechanisms by which estrogens exert this
action remain unknown [23–25].
We found decreased TRAP levels in patients with mood disor-
ders (either depression or BD) compared to controls. Moreover,
there was an inverse correlation between TRAP and severity of
depression. Those results corroborate previous data that mood dis-
orders are accompanied by lowered antioxidant levels, either total
plasma antioxidant activity or speciﬁc antioxidants and increased
OS [2,26–28]. The differences between patients with mood
n-dichotomized) TRAP levels (higher plasma TRAP as reference group) as dependent
p Odds ratio CI lower CI upper
0.032 0.39 0.16 0.92
0.002 0.15 0.05 0.51
0.018 5.42 1.34 21.91
<0.001 0.89 0.84 0.94
<0.001 0.17 0.10 0.29
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isorders and normal controls, however, were no longer signiﬁ-
ant after considering the effects of the other variables, suggesting
hat the association between mood disorders and TRAP levels are
ediated by other variables.
Surprisingly, the results of this study show that plasma TRAP lev-
ls are signiﬁcantly and positively correlated to BMI. In the ATTICA
tudy, on the other hand, obese and overweight males and females
howed lower total antioxidant capacity concentrations as com-
ared to normal weight individuals [29]. In accordance with the
TTICA study, the Framingham offspring cohort, in which a series
f laboratory assessments, obesity measures, OS and cardiovascu-
ar risk factors were measured, showed that obesity, particularly
entral obesity, was an independent positive predictor for systemic
S [30]. Obesity is known to increase OS in normal volunteers and
linical populations of all ages as indicated by increased lipid perox-
dation [31]. Abdominal and hepatic fat increases lipid peroxidation
hrough excess of free fatty acids, lipoprotein-bound lipids and
ytokines [32]. Nevertheless, TRAP levels mainly reﬂect the antiox-
dant potential of urate (35–65%). There is evidence that uric acid
s signiﬁcantly related to the BMI  [33]. Therefore, our ﬁndings that
lasma TRAP levels are related to BMI  may  be explained by the
ffects of uric acid, which is positively associated with BMI.
This study has strengths and limitations which need to be
oted in interpreting the results. In the present study, we con-
rolled statistically for effects of ethnicity, drug state, including
se of psychotropic medication and statins, and use of alcohol. A
rst limitation is that this study is cross sectional and therefore
o deductions can be made on causal relationships. A follow-up
tudy should be carried out to delineate the interrelationships
etween TRAP plasma levels and uric acid, on the one hand, and
MI  and gender, on the other. Lastly, in this study we examined the
ffects of current TUD deﬁned as patients with nicotine depend-
nce who were current smokers. Thus, our study design does not
llow examination of the chronic versus acute effects of smoking
obacco.
In conclusion, TRAP levels are signiﬁcantly predicted by higher
lasma PON1 activity, the RR functional genotype, non smoking by
R carriers, gender and BMI. Plasma PON1 activity, PON1 genotypes
nd an interaction between PON1 Q192R genotypes and TUD con-
ribute signiﬁcantly to plasma TRAP levels, independently of the
ffects of gender and BMI.
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